Predictive Oncology Inc.
POAI
$0.95
$0.000.00%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 0.18% | -23.89% | -40.36% | -58.34% | -31.04% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.18% | -23.89% | -40.36% | -58.34% | -31.04% |
| Cost of Revenue | 46.49% | 4.71% | -15.46% | -10.58% | -30.56% |
| Gross Profit | -24.97% | -39.30% | -54.31% | -78.82% | -31.30% |
| SG&A Expenses | -20.78% | -30.70% | -22.22% | -25.67% | -25.72% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -18.81% | -29.44% | -21.94% | -25.18% | -25.87% |
| Operating Income | 20.53% | 30.07% | 19.49% | 21.11% | 25.36% |
| Income Before Tax | 26.47% | 31.01% | 20.49% | 37.28% | 39.13% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 26.47% | 31.01% | 20.49% | 37.28% | 39.13% |
| Earnings from Discontinued Operations | 50.43% | -13.46% | -151.51% | -544.13% | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 30.35% | 26.33% | 9.44% | 24.18% | 27.34% |
| EBIT | 20.53% | 30.07% | 19.49% | 21.11% | 25.36% |
| EBITDA | 19.94% | 28.94% | 16.67% | 16.85% | 21.70% |
| EPS Basic | 59.00% | 49.94% | 27.41% | 34.06% | 31.29% |
| Normalized Basic EPS | 57.18% | 53.10% | 35.57% | 29.82% | 28.53% |
| EPS Diluted | 58.98% | 49.87% | 27.23% | 33.93% | 31.23% |
| Normalized Diluted EPS | 57.18% | 53.10% | 35.57% | 29.82% | 28.53% |
| Average Basic Shares Outstanding | 74.38% | 54.08% | 35.75% | 20.43% | 6.33% |
| Average Diluted Shares Outstanding | 74.38% | 54.08% | 35.75% | 20.43% | 6.33% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |